Overall, sCD163 plasmatic levels were higher in COVID-19 patients compared to HD (1209 [863-1563] and 777 [458-1169], respectively; p<0.0001) (Figure 1A) as well as in ARDS group compared to non-ARDS one (1359 [967-1814] and 1126 [819-1381], respectively; p=0.0230) (Figure 1B). Here, CD163 is linked to COVID-19.